enoxaparin, abciximab. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
Amobarbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
enoxaparin, anagrelide. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
Alpha-antithrombin and enoxaparin enhance anticoagulation. Avoid or use alternative medications.
Antithrombin III and enoxaparin enhance anticoagulation. Avoid or use alternative medications.
Enoxaparin and apixaban enhance anticoagulation. Avoid or use alternative medications.
Argatroban and enoxaparin enhance anticoagulation. Avoid or use alternative medications.
Azithromycin increases the effects of enoxaparin by reducing its metabolism. Avoid or use alternative medications.
Bazedoxifene/conjugated estrogens reduce the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Bemiparin and enoxaparin increase anticoagulation. Avoid or use alternative medications.
Bivalirudin and enoxaparin enhance anticoagulation. Avoid or use alternative medications.
Butabarbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Butalbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Capecitabine potentiates the effect of enoxaparin through an unspecified mechanism of interaction. Avoid or use alternative medications. An additional risk of bleeding with enoxaparin may be observed in thrombocytopenic patients receiving antineoplastic agents such as capecitabine.
caplacizumab, enoxaparin. Both enhance the effect of the other by anticoagulation. Avoid or use alternative medications.
Cefamandole potentiates the effect of enoxaparin through pharmacodynamic synergism. Avoid or use alternative medications.
Cefazolin potentiates the effect of enoxaparin through pharmacodynamic synergism. Avoid or use alternative medications.
Cefdinir increases the anticoagulant effect of enoxaparin. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity.
Cefditoren increases the level or effect of enoxaparin by anticoagulation. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity
Cefotetan increases the anticoagulant effect of enoxaparin. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity.
Cefoxitin increases the level or effect of enoxaparin by anticoagulation. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity
Cefpodoxime increases the level or effect of enoxaparin by anticoagulation. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity
Ceftriaxone increases the anticoagulant effect of enoxaparin. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity.
Cefuroxime increases the level or effect of enoxaparin by anticoagulation. Avoid or use alternative medications. Cephalosporins can decrease prothrombin activity
enoxaparin, cilostazol. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
Clarithromycin increases the effect of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.
Conjugated estrogens decrease the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Dabigatran and enoxaparin enhance anticoagulation. Avoid or use alternative medications. Caution is advised as both drugs have the potential to cause bleeding. Simultaneous use may increase the risk of bleeding.
Dalteparin and enoxaparin increase anticoagulation. Avoid or use alternative medications.
enoxaparin, dipyridamole. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
edoxaban, enoxaparin. Both increase the toxicity of the other by anticoagulation. Avoid or use alternative medications. Both drugs can cause bleeding, so monitor closely. Immediately assess any signs or symptoms of blood loss. Long-term concomitant treatment with edoxaban and other anticoagulants is not recommended. Short-term concomitant use may be required in patients transitioning to or from edoxaban.
enoxaparin, eptifibatide. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
Erythromycin base enhances the effects of enoxaparin by decreasing metabolism. Avoid or use alternative medications.
Erythromycin ethyl succinate potentiates the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.
Erythromycin lactobionate potentiates the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.
Erythromycin stearate increases the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.
Estradiol reduces the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Conjugated synthetic estrogens reduce the effects of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Estropipate reduces the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Ethinylestradiol reduces the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Enoxaparin decreases the level or effect of human factor X through pharmacodynamic antagonism. Avoid or use alternative medications. Based on the mechanism of action, factor X is likely to be neutralized by direct and indirect factor Xa inhibitors.
Enoxaparin and fondaparinux increase anticoagulation. Avoid or use alternative medications.
Enoxaparin and heparin enhance anticoagulation. Avoid or use alternative medications.
intrauterine levonorgestrel, enoxaparin. Both reduce the effects of the other through pharmacodynamic antagonism. Avoid or use alternative medications. Risk of thromboembolic diseases.
oral levonorgestrel, enoxaparin. Both reduce the effects of the other through pharmacodynamic antagonism. Avoid or use alternative medications. Risk of thromboembolic diseases.
Liothyronine potentiates the action of enoxaparin through pharmacodynamic synergism. Avoid or use alternative medications.
Mestranol reduces the effect of enoxaparin through pharmacodynamic antagonism. contraindicated. Risk of thromboembolic diseases.
Pentobarbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Enoxaparin and phenindione enhance anticoagulation. Avoid or use alternative medications.
Phenobarbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Piperacillin increases the anticoagulant effect of enoxaparin. Avoid or use alternative medications. Piperacillin can inhibit platelet aggregation.
Primidone decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Enoxaparin and protamine enhance anticoagulation. Avoid or use alternative medications.
Quinine potentiates the effects of enoxaparin through an unknown mechanism. Avoid or use alternative medications.
Roxithromycin increases the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.
Secobarbital decreases the effects of enoxaparin by increasing its metabolism. Avoid or use alternative medications.
Sulfadiazine increases the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.Sulfadiazine potentiates the effect of enoxaparin by competing for plasma protein binding. Avoid or use alternative medications.
Sulfamethoxazole increases the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.Sulfamethoxazole potentiates the effect of enoxaparin by competing for plasma protein binding. Avoid or use alternative medications.
Sulfisoxazole increases the effects of enoxaparin by decreasing its metabolism. Avoid or use alternative medications.Sulfisoxazole potentiates the effect of enoxaparin by competing for plasma protein binding. Avoid or use alternative medications.
desiccated thyroid enhances the action of enoxaparin through pharmacodynamic synergism. Avoid or use alternative medications.
Tibolone potentiates the action of enoxaparin through pharmacodynamic synergism. Avoid or use alternative medications.
enoxaparin, ticlopidine. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
enoxaparin, tirofiban. Each enhances the effects of the other through pharmacodynamic synergism. contraindicated. Increased bleeding risk.
enoxaparin, zanubrutinib. Both enhance the effect of the other by anticoagulation. Avoid or use alternative medications.
Acalabrutinib potentiates the anticoagulant effect of enoxaparin. Caution/Monitoring. Concomitant use of acalabrutinib with antiplatelet agents or anticoagulants may further increase the risk of bleeding. Watch for signs of bleeding and weigh the risk/benefit of stopping acalabrutinib for 3 to 7 days before and after surgery, depending on the type of surgery and the risk of bleeding.
Enoxaparin and aceclofenac enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and acemetacin enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and agrimony enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and alfalfa enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and alteplase enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and American ginseng enhance anticoagulation. Adjust/monitor therapy closely.
amiloride, enoxaparin. Both increase the toxicity of the other through serum potassium. Caution/Monitoring. Both drugs can increase serum potassium levels.
Enoxaparin and Anamu enhance anticoagulation. Caution/Monitoring.
Enoxaparin and aspirin enhance anticoagulation. Caution/Monitoring. Additive effects are intended when both drugs are prescribed as indicated for Unstable Angina, Non-Q-wave IM, and STEMIaspirin, enoxaparin. Both enhance the toxicity of the other through pharmacodynamic synergism. Caution/Monitoring. The need for concomitant use of low-dose aspirin and anticoagulants or antiplatelet agents is common in patients with cardiovascular disease; watch closely.
Enoxaparin and rectal aspirin enhance anticoagulation. Adjust/monitor therapy closely.
Aspirin/citric acid/sodium bicarbonate, enoxaparin. Both enhance the toxicity of the other through pharmacodynamic synergism. Caution/Monitoring. The need for concomitant use of low-dose aspirin and anticoagulants or antiplatelet agents is common in patients with cardiovascular disease; watch closely.Enoxaparin and aspirin/citric acid/sodium bicarbonate enhance anticoagulation. Caution/Monitoring. Additive effects are intended when both drugs are prescribed as indicated for Unstable Angina, Non-Q-wave IM, and STEMI
Azapropazone potentiates the effect of enoxaparin by competing for plasma protein binding. Caution/Monitoring.
Azathioprine decreases the effect of enoxaparin by an unknown mechanism. Caution/Monitoring.
Azficil-T, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Concomitant use with anticoagulants or antiplatelet agents may increase bruising or bleeding at biopsy and/or injection sites; Simultaneous use is not recommended. Decisions about continued use or discontinuation of anticoagulants or antiplatelet agents should be made by a physician.
Enoxaparin increases the toxicity of azilsartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin increases the toxicity of benazepril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
enoxaparin, betrixaban. Each increases the other's stats by anticoagulating. Caution/Monitoring.
budesonide, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Enoxaparin increases the toxicity of candesartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin increases the toxicity of captopril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Carbamazepine lowers enoxaparin levels by increasing metabolism. Caution/Monitoring.
Enoxaparin and celecoxib enhance anticoagulation. Adjust/monitor therapy closely.
Chitosan enhances the effects of enoxaparin by others (see comment). Caution/Monitoring. Comment: Chitosan can reduce GI absorption of vitamin K and increase anticoagulant effect.
Enoxaparin and choline magnesium trisalicylate increase anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and cinnamon enhance anticoagulation. Adjust/monitor therapy closely.
Citalopram potentiates the action of enoxaparin through pharmacodynamic synergism. Caution/Monitoring. The combination can increase the risk of bleeding.
enoxaparin, clopidogrel. Each enhances the effects of the other through pharmacodynamic synergism. Adjust/monitor therapy closely. Increased risk of bleeding; Additive effects are intended when both drugs are prescribed according to the directions for ACS.
Enoxaparin increases the toxicity of Clostridium histolyticum collagenase by anticoagulation. Caution/Monitoring. Clostridium histolyticum collagenase has a high incidence of bruising/bruising at the injection site; Avoid concomitant use of anticoagulants (except low-dose aspirin, ie up to 150 mg/day).
Conjugated vaginal estrogens decrease the effect of enoxaparin through pharmacodynamic antagonism. Adjust/monitor therapy closely. Risk of thromboembolic diseases.
Enoxaparin and cordyceps enhance anticoagulation. Adjust/monitor therapy closely.
Corn silk decreases the effect of enoxaparin through pharmacodynamic antagonism. Caution/Monitoring. Cornsilk contains vitamin K; take a consistent amount every day.
cortisone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Cyclophosphamide potentiates the effects of enoxaparin by an unknown mechanism. Caution/Monitoring. Due to the potential thrombocytopenic effects of cyclophosphamide, an additional risk of bleeding may be observed in patients receiving concomitant anticoagulants.
Enoxaparin and Danshen enhance anticoagulation. Caution/Monitoring.
deferasirox, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Gastric ulcers and gastrointestinal bleeding have been reported in patients taking deferasirox. Be careful with concomitant use with other medicines known to increase the risk of stomach ulcers or stomach bleeding, including anticoagulants.
deflazacort, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Enoxaparin and devil's claw increase anticoagulation. Caution/Monitoring.
dexamethasone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Enoxaparin and diclofenac enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and diflunisal increase anticoagulation. Adjust/monitor therapy closely.Diflunisal enhances the effects of enoxaparin by competing for binding to plasma proteins. Caution/Monitoring.
Enoxaparin and dong quai enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of enalapril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and epoprostenol enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of eprosartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Ethanol potentiates the effects of enoxaparin by an unknown mechanism. Caution/Monitoring. Acute EtOH intoxication.
Enoxaparin increases ethotoin levels by an unknown mechanism. Caution/Monitoring.etotoin, enoxaparin. Other (see comment). Caution/Monitoring. Comment: The anticonvulsant hydantoin initially increases the anticoagulant effect, then this effect decreases with continued use (longer than 2 weeks). Multiple mechanisms are involved, including enzyme induction, competition at the plasma protein binding site, and additive effects on prothrombin time.
Enoxaparin and etodolac increase anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and fenbufen enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and fennel enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and fenoprofen enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and feverfew increase anticoagulation. Adjust/monitor therapy closely.
fish oil, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Patients taking fish oil and an anticoagulant or other drug that affects blood clotting should be monitored regularly because of the potential increased risk of bleeding. .
Fish oil triglycerides increase the level or effect of enoxaparin by anticoagulation. Caution/Monitoring. Prolonged bleeding in patients taking antiplatelet drugs or anticoagulants and oral omega-3 fatty acids. Regularly monitor bleeding time in patients receiving fish oil triglycerides and concomitant antiplatelet or anticoagulant drugs.
fludrocortisone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Fluorouracil potentiates the effect of enoxaparin through an unspecified mechanism of interaction. Caution/Monitoring. Due to the thrombocytopenic effect of fluorouracil, an additional risk of bleeding may be observed in patients receiving concomitant anticoagulants.
Enoxaparin and flurbiprofen enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and forskolin enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of fosinopril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin increases fosphenytoin levels by an unknown mechanism. Caution/Monitoring.fosphenytoin, enoxaparin. Other (see comment). Caution/Monitoring. Comment: The anticonvulsant hydantoin initially increases the anticoagulant effect, then this effect decreases with continued use (longer than 2 weeks). Multiple mechanisms are involved, including enzyme induction, competition at the plasma protein binding site, and additive effects on prothrombin time.
Enoxaparin and garlic increase anticoagulation. Adjust/monitor therapy closely.
Gemcitabine potentiates the effect of enoxaparin through an unspecified mechanism of interaction. Caution/Monitoring. Due to the thrombocytopenic effect of gemcitabine, an additional risk of bleeding may be observed in patients receiving concomitant anticoagulants.
Enoxaparin and ginger enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and ginkgo biloba enhance anticoagulation. Adjust/monitor therapy closely.
Intranasal glucagon potentiates the effects of enoxaparin by an unknown mechanism. Caution/Monitoring.
green tea, enoxaparin. Other (see comment). Caution/Monitoring. Comment: The combination can increase the risk of bleeding, caution is advised.
enoxaparin, hemin. Each enhances the effect of the other through anticoagulation. Caution/Monitoring. The breakdown product of hemin (ie, hematin) can cause coagulopathy (eg, thrombocytopenia, platelet degranulation) and mild anticoagulant effects.
Enoxaparin and horse chestnut seed enhance anticoagulation. Adjust/monitor therapy closely.
hydrocortisone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Ibrutinib increases the level or effect of enoxaparin by anticoagulation. Caution/Monitoring. Ibrutinib may increase the risk of bleeding in patients receiving antiplatelet or anticoagulant therapy who need to be monitored for signs of bleeding.
Enoxaparin and ibuprofen increase anticoagulation. Adjust/monitor therapy closely.
IV enoxaparin and ibuprofen enhance anticoagulation. Adjust/monitor therapy closely.
icosapent, enoxaparin. Each enhances the effects of the other through pharmacodynamic synergism. Caution/Monitoring. Icosapent can prolong bleeding time; monitor regularly when used with other drugs that affect bleeding.
imatinib, enoxaparin. Both increase the toxicity of the other to the other (see comment). Adjust/monitor therapy closely. Comment: Imatinib can cause thrombocytopenia; increased risk of bleeding with the simultaneous use of imatinib with anticoagulants, NSAIDs, antiplatelets and thrombolytics; Patients who require anticoagulation during treatment with imatinib should receive LMWH or unfractionated heparin instead of warfarin due to the multiple mechanisms of interaction of imatinib with warfarin.
Enoxaparin and indomethacin enhance anticoagulation. Adjust/monitor therapy closely.
Iodine (radioactive) decreases the effect of enoxaparin through pharmacodynamic antagonism. Caution/Monitoring.
Enoxaparin increases the toxicity of irbesartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and ketoprofen enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and ketorolac enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and intranasal ketorolac enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of lisinopril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Lofepramine increases enoxaparin levels by decreasing metabolism. Caution/Monitoring.
Enoxaparin and lornoxicam enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of losartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and meclofenamate enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and mefenamic acid enhance anticoagulation. Adjust/monitor therapy closely.
Melatonin enhances the anticoagulant effect of enoxaparin. Caution/Monitoring. Melatonin can shorten the prothrombin time.
Enoxaparin and meloxicam enhance anticoagulation. Adjust/monitor therapy closely.
Methimazole reduces the effect of enoxaparin through pharmacodynamic antagonism. Caution/Monitoring.
methylprednisolone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Enoxaparin increases and mistletoe decreases anticoagulation. The interaction effect is not clear, be careful. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of moexipril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and nabumetone enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and naproxen enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases and nettle decreases anticoagulation. The interaction effect is not clear, be careful. Adjust/monitor therapy closely.
Nintedanib increases the anticoagulant effect of enoxaparin. Caution/Monitoring. Nintedanib is a VEGFR inhibitor and may increase the risk of bleeding; monitoring of patients on full anticoagulant therapy; Monitor bleeding closely and adjust therapy as needed.
Enoxaparin increases the toxicity of olmesartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Omega-3 carboxylic acids, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Patients taking omega-3 acids and an anticoagulant or other drugs that affect coagulation should be monitored regularly because of the potential increased risk of bleeding.
Omega-3 fatty acids, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Patients taking omega-3 fatty acids and taking an anticoagulant or other drug that affects clotting should be monitored regularly because of the potential increased risk of bleeding. .
Enoxaparin and oxaprozin enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and Panax Ginseng enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and parecoxib enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and pau d'arco increase anticoagulation. Adjust/monitor therapy closely.
Pegaspargase potentiates the action of enoxaparin through pharmacodynamic synergism. Caution/Monitoring. Increased risk of bleeding events.
Enoxaparin increases the toxicity of perindopril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin increases phenytoin levels by an unknown mechanism. Caution/Monitoring.phenytoin, enoxaparin. Other (see comment). Caution/Monitoring. Comment: The anticonvulsant hydantoin initially increases the anticoagulant effect, then this effect decreases with continued use (longer than 2 weeks). Multiple mechanisms are involved, including enzyme induction, competition at the plasma protein binding site, and additive effects on prothrombin time.
Enoxaparin and phytoestrogens enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and piroxicam enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin reduces the effect of porfimer through pharmacodynamic antagonism. Caution/Monitoring.
enoxaparin, prasugrel. Each enhances the effects of the other through pharmacodynamic synergism. Caution/Monitoring. Increased bleeding risk.
prednisolone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
prednisone, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
Propafenone increases the effects of enoxaparin by decreasing its metabolism. Caution/Monitoring.
Propylthiouracil reduces the effect of enoxaparin through pharmacodynamic antagonism. Caution/Monitoring.
Enoxaparin increases the toxicity of quinapril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin increases the toxicity of ramipril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and Reishi enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and reteplase enhance anticoagulation. Adjust/monitor therapy closely.
Rifabutin lowers enoxaparin levels by increasing metabolism. Caution/Monitoring.
rivaroxaban, enoxaparin. Both enhance the effect of the other by anticoagulation. Caution/Monitoring. Avoid concomitant use of rivaroxaban with other anticoagulants due to the increased risk of bleeding, except during therapeutic transition periods when patients should be closely monitored. Monitor signs/symptoms of blood loss.
Enoxaparin increases the toxicity of sacubitril/valsartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and salicylates (non-ASA) enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and salsalate enhance anticoagulation. Adjust/monitor therapy closely.
Saw palmetto increases the toxicity of enoxaparin through an unspecified mechanism of interaction. Caution/Monitoring. It can increase the risk of bleeding.
Enoxaparin and Siberian ginseng enhance anticoagulation. Adjust/monitor therapy closely.
spironolactone, enoxaparin. Both increase the toxicity of the other through serum potassium. Caution/Monitoring. Both drugs can increase serum potassium levels.
Enoxaparin and sulfasalazine enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and sulindac enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of telmisartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Enoxaparin and tenecteplase enhance anticoagulation. Adjust/monitor therapy closely.
ticagrelor, enoxaparin. Both enhance the effect of the other by anticoagulation. Caution/Monitoring. Increased risk of bleeding with concomitant use of drugs that increase the risk of bleeding.
Tipranavir potentiates the effect of enoxaparin through pharmacodynamic synergism. Caution/Monitoring. Tipranavir has a weak anticoagulant effect that may increase the risk of bleeding.
Enoxaparin and tolfenamic acid enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin and tolmetin enhance anticoagulation. Adjust/monitor therapy closely.
Enoxaparin increases the toxicity of trandolapril to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
Triamcinolone acetonide suspension for injection, enoxaparin. Other (see comment). Caution/Monitoring. Comment: Corticosteroids can reduce the anticoagulant effect by increasing the blood's ability to clot; on the other hand, they can impair vascular integrity and thus increase the risk of bleeding. Monitor the INR closely.
triamterene, enoxaparin. Both increase the toxicity of the other through serum potassium. Caution/Monitoring. Both drugs can increase serum potassium levels.
Triclofos potentiates the effect of enoxaparin through an unspecified mechanism of interaction. Caution/Monitoring.
Enoxaparin increases the toxicity of valsartan to others (see comment). Caution/Monitoring. Comment: Low molecular weight heparins can suppress adrenal secretion of aldosterone, possibly causing hyperkalemia.
enoxaparin, vorapaxar. Both enhance the effect of the other by anticoagulation. Caution/Monitoring. Concomitant use of anticoagulants, antiplatelet agents or other medicinal products that affect coagulation should be monitored regularly due to the potential for increased risk of bleeding.
Vortioxetine and enoxaparin enhance anticoagulation. Caution/Monitoring.